Form 4: Rhythm Pharmaceuticals Director Jennifer Good Executes Stock Options and Sells Shares

Director Jennifer Good exercised stock options and sold shares of Rhythm Pharmaceuticals on September 17, 2024, according to a Form 4 filing.

Summary

• On September 17, 2024, Jennifer L. Good, a director of Rhythm Pharmaceuticals, exercised stock options to acquire a total of 31,751 shares of common stock at prices of $22.93, $21.37, and $18.99.
• Simultaneously, Good sold 31,751 shares of common stock at a weighted average price of $52.4016, with individual sales ranging from $52.00 to $53.00 per share.
• Following these transactions, Good directly owns 3,000 shares of Rhythm Pharmaceuticals common stock and no derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather reports factual information.

Industry Context

This filing reflects insider trading activity, which is common for executives and directors of publicly traded companies. The use of a 10b5-1 plan suggests the transactions were pre-planned to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Insider trading activity is a normal part of the stock market.
• Directors and officers often have stock options as part of their compensation packages, and exercising these options and selling shares is a common practice.
• The use of a 10b5-1 plan is a standard method for insiders to sell shares without raising concerns about insider trading.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
• The transactions themselves have a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates